<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080415</url>
  </required_header>
  <id_info>
    <org_study_id>DCV SOF T 2017</org_study_id>
    <nct_id>NCT03080415</nct_id>
  </id_info>
  <brief_title>Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir &amp; Daclatasvir</brief_title>
  <official_title>The Safety and Efficacy of Sofosbuvir &amp; Daclatasvir Combined Therapy for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yassin Abdelghaffar Charity Center for Liver Disease and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Egyptian Cure Bank NGO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Friends of Liver Patients in the Arab World (SLPAW)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yassin Abdelghaffar Charity Center for Liver Disease and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, uncontrolled pilot study of thirty chronic HCV infected patients carried out
      at Yassin Abdel Ghaffar Charity Center for Liver Disease and Research. The aim of this study
      is to investigate the safety &amp; efficacy of combined therapy sofosbuvir (SOF) and daclatasvir
      (DCV) for treating HCV Genotype 4 in children aged 8 to 18. Due to previous positive results
      in other clinical studies of this drug it is expected that the drug will have high safety and
      high efficacy. Safety will be measured by checking for adverse effects, while efficacy will
      be measured by Real-Time Quantitative Polymerase Chain Reaction (qPCR) detecting viral
      nucleic acids in blood samples.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 18, 2017</start_date>
  <completion_date type="Anticipated">June 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All of the participants will be receiving combined therapy of sofosbuvir and daclatasvir for 12 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>During the 12 weeks of treatment.</time_frame>
    <description>The presence of any adverse effects will be used to characterize this outcome measure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sustained Viral Clearance</measure>
    <time_frame>At Week 12 after end of treatment.</time_frame>
    <description>HCV RNA qPCR will be used to determine if the target of viral clearance has been established. Detection limit of the kit is 12 IU/ml.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis C Genotype 4</condition>
  <arm_group>
    <arm_group_label>Combined Therapy SOF and DCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combined Therapy SOF and DCV</intervention_name>
    <description>1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day
SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients
DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients</description>
    <arm_group_label>Combined Therapy SOF and DCV</arm_group_label>
    <other_name>sofosbuvir</other_name>
    <other_name>daclatasvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 8-18 years

          2. Sex: both sexes

          3. Na√Øve patients, with chronic HCV infection

        Exclusion Criteria:

          1. Co-infection with Hepatitis B virus (HBV)

          2. Other associated chronic liver illness

          3. Cirrhotic patients (as indicated by biopsy, fibroscan(F4)

          4. Patients with history of hematemesis (non cirrhotic portal hypertension)

          5. Patients on drugs known to interact unfavorably with SOF (Amiodarone,..)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawhida Y. Abdel Ghaffar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor Yassin Abdel Ghaffar Charity Center for Liver Disease and Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Professor Yassin Abdel Ghaffar Charity Center for Liver Disease and Research</name>
      <address>
        <city>Nasr City</city>
        <state>Cairo</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141. Epub 2013 Feb 4. Review.</citation>
    <PMID>23172780</PMID>
  </reference>
  <reference>
    <citation>Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther. 2014 Jan;39(2):137-47. doi: 10.1111/apt.12551. Epub 2013 Nov 19. Review.</citation>
    <PMID>24251930</PMID>
  </reference>
  <reference>
    <citation>Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015 Jan;61(1):77-87. doi: 10.1002/hep.27259. Epub 2014 Jul 28.</citation>
    <PMID>25069599</PMID>
  </reference>
  <reference>
    <citation>Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014 Nov;61(1 Suppl):S45-57. doi: 10.1016/j.jhep.2014.07.027. Epub 2014 Jul 30. Review.</citation>
    <PMID>25086286</PMID>
  </reference>
  <reference>
    <citation>Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis. 2000 Sep;182(3):698-707. Epub 2000 Aug 17.</citation>
    <PMID>10950762</PMID>
  </reference>
  <reference>
    <citation>Reker C, Islam KM. Risk factors associated with high prevalence rates of hepatitis C infection in Egypt. Int J Infect Dis. 2014 Aug;25:104-6. doi: 10.1016/j.ijid.2014.02.003. Epub 2014 May 24.</citation>
    <PMID>24865321</PMID>
  </reference>
  <reference>
    <citation>Zahran KM, Badary MS, Agban MN, Abdel Aziz NH. Pattern of hepatitis virus infection among pregnant women and their newborns at the Women's Health Center of Assiut University, Upper Egypt. Int J Gynaecol Obstet. 2010 Nov;111(2):171-4. doi: 10.1016/j.ijgo.2010.06.013. Epub 2010 Aug 12.</citation>
    <PMID>20708181</PMID>
  </reference>
  <reference>
    <citation>El Naghi S, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol. 2014 Apr 28;20(16):4681-91. doi: 10.3748/wjg.v20.i16.4681.</citation>
    <PMID>24782620</PMID>
  </reference>
  <reference>
    <citation>(CDER) USDoHaHSFaDACfDEaR. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment 2013. Available from: http://www.fda. gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm225333.pdf</citation>
  </reference>
  <reference>
    <citation>Peter J, Nelson DR. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. Liver Int. 2015 Jan;35 Suppl 1:65-70. doi: 10.1111/liv.12718. Review.</citation>
    <PMID>25529089</PMID>
  </reference>
  <reference>
    <citation>Papastergiou V, Karatapanis S. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6. World J Clin Cases. 2015 Mar 16;3(3):210-20. doi: 10.12998/wjcc.v3.i3.210. Review.</citation>
    <PMID>25789294</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>March 31, 2017</last_update_submitted>
  <last_update_submitted_qc>March 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yassin Abdelghaffar Charity Center for Liver Disease and Research</investigator_affiliation>
    <investigator_full_name>Dr. Tawhida Yassin Abdel Ghaffar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

